Journey with AxxessBio:
Stay informed with our latest news, press releases and shared milestones

Partnership with EUSA Pharma brings Caphosol for the prevention and treatment of cancer treatment – induced mucositis

In 2016, AxxessBio and EUSA Pharma entered into an exclusive agreement to supply Caphosol Solution and Caphosol Dispersible tablets in selected countries of Southeast Asia.


Caphosol is a mouthwash indicated for the prevention and treatment of oral mucositis due to cancer chemotherapy or radiation. It is a supersaturated solution of calcium and phosphate that coats the lining of the mouth, the tongue and oropharynx maintaining the integrity of the oral cavity. It can also be used to treat severe mouth dryness.


Oral mucositis is a debilitating complication of cancer therapy impacting the well- being of the patient and the outcome of treatment. It is often associated with pain, inability to drink or eat, and could be the portal for infection. 


EUSA Pharma is a UK based global pharmaceutical company. It is committed to providing solutions in oncology and rare diseases continuously striving to confront gaps in patient care. For more information on the company and its products please visit


Interested in Partnering Up?

At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia